We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Acrongenomics Retains KGMC Group
News

Acrongenomics Retains KGMC Group

Acrongenomics Retains KGMC Group
News

Acrongenomics Retains KGMC Group

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Acrongenomics Retains KGMC Group"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Acrongenomics, Inc. has announced that it has retained KGMC Group, LLC of Frankfort, Illinois to introduce its Nano-JETA™ technology platform to the world market.

KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA™ platform, secure publications of this technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.

“Following a year of thorough study, our scientists and Board of Directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer,” Says KGMC Group President Bill Kanatas.

“We are convinced that Nano-JETA™ technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer.”

“Neo-EpCAM™ cancer detection assay is the first application utilizing the Nano-JETA™ technology.”

“More so exciting is that the process takes less than two minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish.”

“Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology.”

Advertisement